This could be attributed to a difference in the intrinsic subtypes between HER2-low and HER2-IHC 0 breast cancer; factors related to reduced aggressiveness, such as low Ki-67 labeling index; the existence of more complex unknown biology related to HER2-low breast cancer. This evidence concerns the gene MKI67 and breast cancer.